Antibody combination, kit and system for detecting peripheral blood monocyte subsets
Through the combination of CD36, CD64, CD14, CD16 antibody and flow cytometry technology, the peripheral blood mononuclear cell subpopulations were identified, and the problem of lack of clear detection methods in the existing technology was solved, and the high incidence of chronic myeloid mononuclear leukemia was achieved. Sensitivity, specific diagnosis simplifies the process and improves diagnostic efficiency.
Patent Information
- Application Number
- CN202410462911.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-17
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-04-17
AI Technical Summary
There is a lack of clear methods in the prior art to detect subpopulations of peripheral blood mononuclear cells, resulting in increased difficulty in early diagnosis and precise diagnosis of chronic myelomonocytic leukemia.
Using CD36 antibody, CD64 antibody, CD14 antibody and CD16 antibody combination, combined with flow cytometry technology, the percentage of classic, intermediate and non-classical monocyte subpopulations can be quickly identified by analyzing the expression patterns of cells, and assisting in the diagnosis of chronic diseases. Granular mononuclear leukemia.
It realizes accurate typing of peripheral blood mononuclear cell subpopulations, improves the sensitivity and specificity of diagnosis, simplifies the detection process, reduces the requirements for analysts' professional knowledge, quickly obtains results, and helps with accurate clinical diagnosis.
Smart Images

Figure CN118330216B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of immunological detection, and more specifically, the present invention relates to an antibody combination, a kit and a system for detecting peripheral blood mononuclear cell subpopulations. Background Art
[0002] Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with manifestations of both myeloproliferative neoplasms (MPN) and myelodysplastic syndrome (MDS). It is common in elderly patients with an incidence of approximately 4 / 100,000. The reported survival of CMML patients ranges from 1 month to >100 months, with most reports of a median survival of 20 to 40 months. Approximately 15 to 30% of cases may progress to AML. Early identification and accurate diagnosis play an important role in the precise treatment and prognosis of patients.
[0003] Peripheral blood mononuclear cell increase is a prominent feature of CMML. The first prerequisite for its diagnostic criteria defined in the 2016 version of the WHO is a continuous increase in peripheral blood mononuclear cells: an absolute value of ≥1×10 9 / L and relative value ≥10%. On this basis, many other detection indicators need to be combined to confirm CMML. The international guidelines stipulate that the phenotype of peripheral blood mononuclear cells in chronic myelomonocytic leukemia is: classical type (MO1), and the phenotype is defined as CD14 bright / CD16 - , proportion ≥94%; intermediate type (MO2), phenotypically defined as CD14 bright / CD16 + , ratio <20%; non-classical (MO3), phenotypically defined as CD14 dim / CD16 + , the proportion is less than 5%.
[0004] In the "Chinese Guidelines for the Diagnosis and Treatment of Chronic Myeloid-Monocytic Leukemia (2021 Edition)", peripheral blood monocyte subset analysis is included in the auxiliary diagnostic criteria, and it is pointed out that using the critical value of classical (MO1) monocyte percentage >94%, the sensitivity of identifying CMML cases is >90%, and the specificity is >95%. A decrease in MO3 monocytes even has the same diagnostic value as an increase in circulating MO1 cells.
[0005] The diagnostic criteria for CMML in the latest 2022 edition of WHO have changed the requirement for peripheral blood mononuclear cells to: absolute value ≥ 0.5 × 10 9 / L and relative value ≥ 10%, and included abnormal subpopulations of peripheral blood monocytes in its support criteria, which improved its diagnostic value in CMML. It can be seen that the auxiliary role of peripheral blood monocyte subpopulation analysis for CMML patients is becoming more and more important, and its clinical application is becoming more and more extensive.
[0006] However, the current international guidelines only define the immune phenotype of peripheral blood monocytes, and do not clearly indicate how to circle out total monocytes or which specific antibody combinations to use to determine the immune phenotype. Summary of the invention
[0007] Based on this, the purpose of the present invention is to provide an antibody combination, a kit and a system for detecting peripheral blood monocyte subpopulations. The antibody combination of the present invention is used to detect peripheral blood monocytes, which can be accurately typed with high sensitivity, strong specificity, and is simple and convenient.
[0008] The technical solutions for achieving the above-mentioned invention objectives include the following.
[0009] In a first aspect, the present invention provides an antibody combination for detecting peripheral blood monocyte subpopulations, wherein the antibody combination comprises: CD36 antibody, CD64 antibody, CD14 antibody, CD16 antibody and CD45 antibody.
[0010] The second aspect of the present invention provides the use of the above-mentioned antibody combination for detecting peripheral blood monocyte subsets in the preparation of a kit for auxiliary diagnosis of chronic myelomonocytic leukemia.
[0011] The third aspect of the present invention provides a kit for detecting peripheral blood monocyte subpopulations, comprising the above-mentioned antibody combination for detecting peripheral blood monocyte subpopulations.
[0012] The fourth aspect of the present invention provides a system for detecting peripheral blood monocyte subpopulations, comprising: a detection module for performing flow cytometry detection on the peripheral blood monocytes to be detected, a data acquisition module for acquiring the flow cytometry detection results, and a data analysis module for analyzing the acquired flow cytometry detection results.
[0013] In a fifth aspect of the present invention, a method for detecting peripheral blood monocyte subpopulations is provided, comprising the following steps: using the above-mentioned antibody combination and system to detect a single cell suspension of peripheral blood to be tested, sequentially analyzing the expression of antibodies to CD45-SSC, CD36-CD64, CD14-CD64 and CD16-CD14 and the ratio of the three monocyte subtypes, to obtain the antibody expression pattern of the peripheral blood to be tested; and then comparing the antibody expression pattern with that of a normal control population.
[0014] The present invention has the following beneficial effects:
[0015] In the present invention, based on the research experience on peripheral blood monocytes of chronic myeloid-monocytic leukemia, the inventors screened out CD36 antibody, CD64 antibody, CD14 antibody, CD16 antibody and CD45 antibody as an antibody combination to detect peripheral blood monocytes. The antibody combination can identify the target monocyte population, and by sequentially analyzing the expression of CD36-CD64, CD14-CD64, and CD16-CD14 fluorescent antibodies on the target monocyte population, the percentages of the three subpopulations of classical monocytes (MO1), intermediate monocytes (MO2), and non-classical monocytes (MO3) can be quickly obtained, so that the monocyte population with normal immunophenotype or suspected tumor monocytes can be determined based on the immunophenotype and the percentages of the three subpopulations. The present invention rationally applies various antibody indicators, covering a wide range. The antibody combination can be used through multi-parameter flow detection technology to quickly and easily, quickly (it only takes 1 to 2 hours from sample reception to test results), and highly sensitively detect monocyte subpopulations (the present invention uses 1 clinical normal sample and 1 clinical abnormal sample as examples to verify the use of the antibody combination of the present invention to detect peripheral blood mononuclear cells, which is consistent with the clinical test results), which can help clinically diagnose chronic myelomonocytic leukemia (CMML) accurately. In addition, the present invention fixes the analysis template, and the data can be directly analyzed by dragging it in. The operation is simple, which reduces the requirements for the professional knowledge level of analysts and makes up for the limitations of existing detection technologies. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 This is a scatter plot of the immunophenotype CD45-SSC expression of the monocyte subsets of the normal clinical sample to be tested in Example 3 of the present invention.
[0017] Figure 2 This is a scatter plot of the immunophenotype CD36-CD64 expression of the monocyte subsets of the clinical normal sample to be tested in Example 3 of the present invention.
[0018] Figure 3 This is the expression of the immunophenotype CD14-CD64 of the monocyte subsets of the normal clinical sample to be tested in Example 3 of the present invention.
[0019] Figure 4 The immunophenotype CD16-CD14 expression of the monocyte subsets of the normal clinical sample to be tested in Example 3 of the present invention.
[0020] Figure 5 This is a scatter plot of the CD45-SSC expression of the immunophenotype of the monocyte subsets of the abnormal clinical sample to be tested in Example 3 of the present invention.
[0021] Figure 6 This is a scatter plot of the immunophenotype CD36-CD64 expression of the monocyte subsets of the abnormal clinical sample to be tested in Example 3 of the present invention.
[0022] Figure 7 The immunophenotype CD14-CD64 expression of the monocyte subsets of the abnormal clinical sample to be tested in Example 3 of the present invention.
[0023] Figure 8 The immunophenotype CD16-CD14 expression of the monocyte subsets of the abnormal clinical sample to be tested in Example 3 of the present invention.
[0024] Fig. 9 It is a scatter plot of the immunophenotype CD45-SSC expression of the monocyte subsets of the clinical normal sample to be tested in Comparative Example 1 of the present invention.
[0025] Fig.10 The immunophenotype CD16-CD14 expression of the monocyte subsets of the clinical normal sample to be tested in Comparative Example 1 of the present invention.
[0026] Fig.11 It is a scatter plot of the immunophenotype CD45-SSC expression of the monocyte subsets of the clinical abnormal sample to be tested in Comparative Example 1 of the present invention.
[0027] Fig.12 The immunophenotype CD16-CD14 expression of the monocyte subsets of the abnormal clinical sample to be tested in Comparative Example 1 of the present invention. DETAILED DESCRIPTION
[0028] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0029] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in the present invention includes any and all combinations of one or more of the related listed items.
[0030] The experimental methods in the following examples where specific conditions are not specified are generally carried out under conventional conditions, such as those described in Green and Sambrook et al., Molecular Cloning: A Laboratory Manual (2013), or according to the conditions recommended by the manufacturer. The various commonly used chemical reagents used in the examples are all commercially available products.
[0031] In the present invention, in view of the deficiencies of the prior art, an antibody combination, a kit and a system for detecting peripheral blood monocyte subpopulations are provided. After a large number of experiments, the inventors found that by selecting a combination of CD36 antibody, CD64 antibody, CD14 antibody, CD16 antibody and CD45 antibody to detect peripheral blood monocytes, the percentages of the three subpopulations of classical monocytes (MO1), intermediate monocytes (MO2) and non-classical monocytes (MO3) can be quickly, easily and accurately detected, which helps the accurate diagnosis of clinical CMML. In the detection process, CD45-SSC (side scattered light) is first used for gating (CD45 is a common antigen of leukocytes, so CD45 is used as the gating antibody. The expression intensity of CD45 of normal blood cells is: lymphocytes>monocytes>granulocytes. SSC is side scattered light, which is related to the granularity of the cells. The normal expression intensity of side scattered light is: granulocytes>monocytes>lymphocytes. Combining the expression characteristics of CD45 and SSC, lymphocytes, monocytes and granulocytes can be divided into zones, among which lymphocytes are at the position with the strongest CD45 and the lowest SSC, and granulocytes CD45 is weaker than monocytes and the SSC signal is the highest). According to the expression, the cell population is divided into granulocyte group, monocyte group and lymphocyte group, and then the fluorescence expression intensity and ratio of antibodies to CD36-CD64, CD14-CD64 and CD16-CD14 in the target cells (i.e., monocyte group) are analyzed in turn (through The backbone antibodies CD36 and CD64 can identify the total monocyte population and circle the monocytes expressing CD36+CD64+; then the expression of CD16 and CD14 is used to determine the proportion of the subpopulations. Monocytes with a phenotype of CD14+ / CD16- are classical monocytes (MO1), monocytes with a phenotype of CD14+ / CD16+ are intermediate monocytes (MO2), and monocytes with a phenotype of CD14dim / CD16+ are non-classical monocytes (MO3), showing the percentage of the three subpopulations in the total monocytes; finally, the results are judged according to the predetermined analysis logic and judgment criteria - if the antibody expression pattern and percentage of the cells to be tested fall into the antibody expression pattern template of the normal control population, the cells to be tested are judged as normal monocyte subpopulations; if the antibody expression pattern and percentage of the cells to be tested do not fall into the antibody expression pattern template of the normal control population, the cells to be tested are judged as suspected tumor cell populations.
[0032] In some embodiments of the present invention, an antibody combination for detecting peripheral blood monocyte subpopulations is disclosed, including: CD36 antibody, CD64 antibody, CD14 antibody, CD16 antibody and CD45 antibody.
[0033] In some embodiments, the antibodies of the antibody combination are monoclonal antibodies.
[0034] In some of the embodiments, the monoclonal antibody is a fluorescein-labeled antibody, so that the above indicators can be simultaneously detected in a ten-color or more flow cytometer, which has a certain convenience; the fluorescein is selected from: FITC, PE, ECD, APC and KO.
[0035] In some of the embodiments, the CD36 antibody is labeled with fluorescein FITC; the CD64 antibody is labeled with fluorescein PE; the CD14 antibody is labeled with fluorescein ECD; the CD16 antibody is labeled with fluorescein APC; and the CD45 antibody is labeled with fluorescein KO.
[0036] In other embodiments of the present invention, a kit for detecting peripheral blood monocyte subpopulations is disclosed, wherein the kit comprises the above-mentioned antibody combination for detecting peripheral blood monocyte subpopulations.
[0037] In other embodiments of the present invention, the use of the above antibody combination for detecting peripheral blood monocyte subsets in the preparation of a kit for auxiliary diagnosis of chronic myelomonocytic leukemia (CMML) is disclosed.
[0038] In other embodiments of the present invention, a system for detecting peripheral blood monocyte subpopulations is disclosed, comprising: a detection module for performing flow cytometry detection on the peripheral blood monocytes to be detected, a data acquisition module for acquiring the flow cytometry detection results, and a data analysis module for analyzing the acquired flow cytometry detection results.
[0039] In some of the embodiments, the detection template includes a single-cell suspension module (for preparing a single-cell suspension), an incubation module (for combining the single-cell suspension with an antibody for light-proof incubation to perform an antigen-antibody reaction), a resuspension module (for adding hemolysin to the incubated cells, centrifuging, washing, and then resuspending the cells to prepare a suspension) and a measurement module (for performing flow cytometry measurement on the resuspended suspension).
[0040] In other embodiments of the present invention, a method for detecting peripheral blood monocyte subpopulations is disclosed, comprising the following steps: using the above-mentioned antibody combination and system to detect a single cell suspension of peripheral blood to be tested, sequentially analyzing the expression of antibodies to CD45-SSC, CD36-CD64, CD14-CD64 and CD16-CD14 and the ratio of the three monocyte subtypes, to obtain the antibody expression pattern of the peripheral blood to be tested; and then comparing it with the antibody expression pattern template of a normal control population.
[0041] In some of the embodiments, the normal control population antibody expression pattern template is established by the following method: obtaining the flow cytometry detection result data of the normal control population cell population, grouping the nucleated cells by setting a gate, circling the target cell population (i.e., monocytes), and then analyzing the proportions of the three subpopulations MO1, MO2, and MO3.
[0042] In some of the embodiments, the antibody expression pattern of the peripheral blood cells to be tested is established by the following method: obtaining the flow cytometry test result data of the peripheral blood cells to be tested, setting gates to group the nucleated cells according to the method in the antibody expression pattern template of the normal control population, circling the target cell population (i.e., monocytes), and then analyzing the proportion of the three subpopulations MO1, MO2, and MO3 in the target cell population according to the method in the antibody expression pattern template of the normal control population.
[0043] The system for detecting peripheral blood mononuclear cell subsets in this embodiment can refer to the conventional flow cytometry technology for its technical process, and the equipment and consumables used are selected from flow cytometry analysis equipment and consumables, such as flow-specific tubes, oscillators, pipettes and other consumables. The specific sources of some antibodies used in the following embodiments are: CD36FITC (Cat. No. IM0766U, BeckmanCoulter), CD64 PE (Cat. No. IM3601U, BeckmanCoulter), CD14 ECD (Cat. No. B92391, BeckmanCoulter), CD16 APC (Cat. No. 360706, BeckmanCoulter), CD45 KO (Cat. No. B36294, biolegend).
[0044] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.
[0045] Example 1 Antibody combination for detecting peripheral blood monocyte subsets
[0046] This embodiment provides an antibody combination for detecting peripheral blood monocyte subsets, including CD36 antibody, CD64 antibody, CD14 antibody, CD16 antibody and CD45 antibody; the fluorescent labels and dosages of the relevant monoclonal antibodies in the above antibodies are shown in Table 1.
[0047] Table 1
[0048] Fluorescent markers FITC PE ECD APC KO Antibody labeling CD36 CD64 CD14 CD16 CD45 Total amount of antibody Sample volume 5μl 5μl 5μl 5μl 2.5μl 22.5μl
[0049] Note: The commercially available antibodies are tested by concentration gradient to determine the optimal dosage, and the above-mentioned amount of monoclonal antibodies are then placed in the flow cytometry tube No. 1.
[0050] Example 2 System and method for detecting peripheral blood monocyte subsets
[0051] This embodiment provides a system for rapidly detecting peripheral blood monocyte subsets, comprising:
[0052] 1. Detection module
[0053] Perform flow cytometry on cells to be tested, including:
[0054] (1) A single cell suspension module, used for preparing a single cell suspension;
[0055] (2) an incubation module, for incubating the single cell suspension with the antibody combination of Example 1 in the dark for antigen-antibody reaction;
[0056] (3) a resuspension module, used to add hemolysin to the incubated cells, centrifuge, wash, and then resuspend the cells to prepare a suspension;
[0057] (4) a measurement module, used for performing flow cytometry measurement on the resuspended suspension;
[0058] 2. Data acquisition module
[0059] Obtain data on the flow cytometry test results of the cells to be tested; the percentages of the three subpopulations of classical monocytes (MO1, phenotype defined as CD14+ / CD16-), intermediate monocytes (MO2, phenotype defined as CD14+ / CD16+), and non-classical monocytes (MO3, phenotype defined as CD14dim / CD16+) in the total monocytes can be directly obtained.
[0060] 3. Data analysis module
[0061] The acquired data is analyzed, and according to the predetermined analysis logic and judgment criteria, it is determined whether the cells to be tested are suspected tumor monocytes - if the antibody expression pattern and percentage of the cells to be tested fall into the antibody expression pattern template of the normal control population, the cells to be tested are determined to be a normal monocyte subpopulation; if the antibody expression pattern and percentage of the cells to be tested do not fall into the antibody expression pattern template of the normal control population, the cells to be tested are determined to be a suspected tumor cell population.
[0062] This embodiment also provides a method for rapidly detecting peripheral blood mononuclear cell subsets. The specific workflow for detecting peripheral blood mononuclear cell subsets using the above system is as follows:
[0063] 1. Prepare the antibodies in the antibody combination of Example 1 as shown in Table 1.
[0064] 2. Sample processing
[0065] The number of cells in the sample to be tested (peripheral blood) was adjusted to 1×10 6 / ml to make a single cell suspension.
[0066] 3. Sample testing
[0067] (1) Take a flow cytometry tube, label it 1, add a set of antibodies in Example 1, the amount added is 22.5 μl (Table 1), then add 100 μl of the single cell suspension in step 2, vortex to mix, and incubate at room temperature in the dark for 15 min.
[0068] (2) Add 400 μl of Bc hemolysin to the incubated flow tube 1, vortex and shake, let it stand until the hemolysis is clear. After the hemolysis is clear, centrifuge the flow tube 1 at 1500 r / min for 5 min, discard the supernatant, add 2 ml of calf serum, vortex and shake, centrifuge at 1500 r / min for 5 min, and discard the supernatant. Add 400 μl of 1% paraformaldehyde and resuspend.
[0069] (3) Detect flow tube 1 using a Beckman Coulter Navios ten-color flow cytometer to obtain ≥5000 CD36+CD64+ monocytes and analyze their immune phenotype and ratio.
[0070] 4. Data Analysis
[0071] (1) Establish a template for the antibody expression pattern of healthy people
[0072] According to the flow cytometry test results of 40 normal control cell populations, the cells were grouped by setting gates, preferably using CD45-SSC (side scattered light) to set the gate, circle the target cell population, and then analyze the expression of each fluorescent antibody and the proportion of the three monocyte subtypes for this cell population, and select the following antibody pairs in turn: CD45-SSC, CD36-CD64, CD14-CD64, CD16-CD14.
[0073] (2) Establishing the antibody expression pattern of the cells to be tested
[0074] Obtain flow cytometry test result data of the cells to be tested, set gates to group the cells according to the antibody expression pattern of the normal control population, circle the target cell population, and then analyze the expression of each fluorescent antibody in the target cell population according to the antibody expression pattern of the normal control population to obtain the antibody expression pattern of the cells to be tested.
[0075] (3) Analyze the antibody expression pattern of the cells to be tested
[0076] If the antibody expression pattern of the cells to be tested falls into the antibody expression pattern template of the normal control population, the cells to be tested are determined to be a monocyte population with a normal immunophenotype;
[0077] If the antibody expression pattern of the cells to be tested does not fall into the antibody expression pattern template of the normal control population, the cells to be tested are determined to be suspected tumor monocytes.
[0078] Example 3 Verification of consistency between the test results of the detection method of the present invention and the clinical diagnosis results
[0079] The detection method of Example 2 was used to detect monocytes of two test cells (one clinical normal sample + one clinical abnormal sample), and antibody expression patterns and subpopulation analysis were performed to verify whether the detection method of the present invention was consistent with the clinical results.
[0080] 1. Normal Sample
[0081] This sample is a clinical sample with normal physical examination and normal blood monocyte content. The antibody expression pattern analysis was performed according to the following steps:
[0082] 1. Obtain the flow cytometry test result data of the sample to be tested. Use CD45-SSC (side scattered light) to set the gate and divide the cell population into three areas (such as Figure 1 shown), granulocytes ( Figure 1 middle upper area of the ), monocytes ( Figure 1 The right upper area of the Figure 1 There are three areas (the lower right area of the image), and the monocyte area is the target cell group. The immunophenotype analysis of this group of cells will be performed below.
[0083] 2. The CD36-CD64 immunophenotype scatter plot of all nucleated cells is as follows Figure 2 As shown in the figure, it can be seen that the CD36+CD64+ monocytes are 7.97%, which is a normal ratio. The number of monocytes obtained is 10094, and the number of cells meets the requirement (≥5000).
[0084] 3. The scatter plot of CD14-CD64 expression of all nucleated cells is as follows Figure 3 As shown in the figure, it can be seen that CD36+CD64+ monocytes are all positive for CD14 and are all mature monocytes.
[0085] 4. The scatter plot of CD16-CD14 expression of monocyte population is as follows Figure 4 As shown in the figure, according to the expression of CD16 and CD14, they are divided into three subgroups. It can be seen that classical monocytes (MO1, phenotype defined as CD14+ / CD16-) account for 90.24% of monocytes, intermediate monocytes (MO2, phenotype defined as CD14+ / CD16+) account for 7.61% of monocytes, and non-classical monocytes (MO3, phenotype defined as CD14dim / CD16+) account for 0.54% of monocytes.
[0086] Therefore, the cell population of the monocyte subpopulation of the sample to be tested is within the antibody expression pattern template of the normal control population, and the classical monocyte (MO1) is less than 94%, indicating that the patient is not chronic myelomonocytic leukemia (non-CMML), which is consistent with the clinical diagnosis results.
[0087] 2. Abnormal Samples
[0088] This sample is a peripheral blood specimen from a patient who has been clinically diagnosed with CMML. The antibody expression pattern analysis was performed according to the following steps:
[0089] 1. Obtain the flow cytometry test result data of the sample to be tested. Use CD45-SSC (side scattered light) to set the gate, and divide the cell population into 3 areas according to the expression of CD45-SSC, such as Figure 5 The following are granulocytes ( Figure 5 middle upper area of the ), monocytes ( Figure 5 The right upper area of the Figure 5 The lower right area of the image), the mononuclear cell area is the target cell population, and the immunophenotype analysis of this group of cells will be performed below.
[0090] 2. The CD36-CD64 immunophenotype scatter plot of all nucleated cells is as follows Figure 6 As shown in the figure, it can be seen that the CD36+CD64+ monocytes account for 15.84%, and the proportion is increased. The number of monocytes obtained is 15772, and the number of cells meets the requirement (≥5000).
[0091] 3. The scatter plot of CD14-CD64 expression of all nucleated cells is as follows Figure 7 As shown in the figure, it can be seen that CD36+CD64+ monocytes are all positive for CD14 and are all mature monocytes.
[0092] 4. The scatter plot of CD16-CD14 expression of monocyte population is as follows Figure 8 As shown in the figure, according to the expression of CD16 and CD14, they are divided into three subgroups. It can be seen that classical monocytes (MO1, phenotype defined as CD14+ / CD16-) account for 98.39% of monocytes, intermediate monocytes (MO2, phenotype defined as CD14+ / CD16+) account for 0.48% of monocytes, and non-classical monocytes (MO3, phenotype defined as CD14dim / CD16+) account for 0.21% of monocytes.
[0093] The above immunophenotypes all indicate that the cell population of the sample to be tested is not in the antibody expression pattern template of the normal control population, and the proportion of classical mononuclear (MO1) is 98.39%, which is greater than 94%, indicating that the patient has chronic myelomonocytic leukemia (CMML), which is consistent with the clinical diagnosis results.
[0094] Therefore, based on the above results, the detection results obtained by using the detection method of the present invention to detect clinical samples are consistent with the clinical results. The antibody combination and detection method of the present invention are of great value for the diagnosis of CMML.
[0095] Comparative Example Using Other Antibody Combinations to Detect Mononuclear Cells in the Test Cells
[0096] The detection method of Example 2 was used to detect the monocytes of the two cells to be detected in Example 3, and antibody expression patterns and subpopulation analysis were performed, except that different antibody combinations were used.
[0097] 1. Normal Sample
[0098] The sample is a clinical sample with normal physical examination and normal monocyte content in blood routine (same as Example 3). The antibody combination used is CD64-PE, CD14-ECD, CD16-APC, CD45-KO. The acquired data is analyzed for antibody expression pattern according to the following steps:
[0099] 1. Obtain the flow cytometry test result data of the sample to be tested. Use CD45-SSC (side scattered light) to set the gate, and circle the target cell population according to the expression of CD45-SSC: total monocytes ( Fig. 9 The upper right area of the image shows that the proportion of total monocytes is 7.92%. The immunophenotype analysis of this group of cells will be performed below.
[0100] 2. The scatter plot of CD16-CD14 expression of total monocyte population is as follows Fig.10 As shown in the figure, according to the expression of CD16 and CD14, they are divided into three subgroups. It can be seen that classical monocytes (MO1, phenotype defined as CD14+ / CD16-) account for 75.61% of monocytes, intermediate monocytes (MO2, phenotype defined as CD14+ / CD16+) account for 10.80% of monocytes, and non-classical monocytes (MO3, phenotype defined as CD14dim / CD16+) account for 6.45% of monocytes.
[0101] Using this antibody combination to detect the monocyte subsets of the sample to be tested, the proportion of classical monocytes (MO1) was 75.61%, which is less than 94%, indicating that the patient is not chronic myelomonocytic leukemia (non-CMML), which is consistent with the clinical diagnosis results. Fig.10 As shown, 7.13% of the cells in the L-region do not express CD16 / CD14, indicating that the total monocyte population circled only by CD45-SSC may be mixed with other cells (such as some small granulocytes and some large lymphocytes). The total monocytes are impure, which will directly affect the proportion of subpopulations and lead to inaccurate results.
[0102] 2. Abnormal Samples
[0103] The sample is a peripheral blood sample of a patient who has been clinically diagnosed with CMML (same as Example 3). The antibody combination used is CD64-PE, CD14-ECD, CD16-APC, CD45-KO, and the acquired data is analyzed for antibody expression pattern according to the following steps:
[0104] 1. Obtain the flow cytometry test result data of the sample to be tested. Use CD45-SSC (side scattered light) to set the gate, and circle the target cell population according to the expression of CD45-SSC: total monocytes ( Fig.11 The right upper area of the image shows that the proportion of total monocytes is 15.75%. The immunophenotype analysis of this group of cells will be performed below.
[0105] 2. The scatter plot of CD16-CD14 expression of total monocyte population is as follows Fig.12 As shown in the figure, according to the expression of CD16 and CD14, they are divided into three subgroups. It can be seen that classical monocytes (MO1, phenotype defined as CD14+ / CD16-) account for 85.24% of monocytes, intermediate monocytes (MO2, phenotype defined as CD14+ / CD16+) account for 1.11% of monocytes, and non-classical monocytes (MO3, phenotype defined as CD14dim / CD16+) account for 3.79% of monocytes.
[0106] The above immunophenotypes all indicate that the cell population of the sample to be tested has a classical mononuclear (MO1) ratio of 85.24% in the antibody expression pattern template of the normal control population, which is less than 94%, indicating that the patient is not chronic myelomonocytic leukemia (CMML), which is inconsistent with the clinical diagnosis results.
[0107] Therefore, combining the results of one and two, it can be seen that on the basis of the CD45-SSC gate, adding CD36 antibody and using CD36-CD64 to circle the total monocyte population is more precise and ensures that the percentage of subsequent monocyte subset analysis is more accurate.
[0108] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0109] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. An antibody combination for detecting peripheral blood mononuclear cell subsets, characterized in that: The antibody combination consists of CD36 antibody, CD64 antibody, CD14 antibody, CD16 antibody and CD45 antibody.
2. The antibody combination for detecting peripheral blood mononuclear cell subsets according to claim 1, characterized in that: The antibodies of the antibody combination are monoclonal antibodies.
3. The antibody combination for detecting peripheral blood mononuclear cell subsets according to claim 2, characterized in that: The monoclonal antibody is a fluorescein-labeled antibody; the fluorescein is selected from: FITC, PE, ECD, APC and KO.
4. The antibody combination for detecting peripheral blood mononuclear cell subsets according to claim 3, characterized in that: The CD36 antibody is labeled with fluorescein FITC; the CD64 antibody is labeled with fluorescein PE; the CD14 antibody is labeled with fluorescein ECD; the CD16 antibody is labeled with fluorescein APC; and the CD45 antibody is labeled with fluorescein KO.
5. Use of the antibody combination for detecting peripheral blood mononuclear cell subsets according to any one of claims 1 to 4 in the preparation of a kit for auxiliary diagnosis of chronic myelomonocytic leukemia.
6. A kit for detecting peripheral blood mononuclear cell subsets, characterized in that: The invention comprises the antibody combination for detecting peripheral blood mononuclear cell subsets as described in any one of claims 1 to 4.
7. The kit for detecting peripheral blood mononuclear cell subsets according to claim 6, characterized in that: The dosage of the CD36 antibody, CD64 antibody, CD14 antibody and CD16 antibody is 4-6 μl, and the dosage of the CD45 antibody is 2-3 μl.
8. A method for detecting peripheral blood mononuclear cell subpopulations, characterized in that: The following steps are involved: Using the antibody combination described in any one of claims 1 to 4, the single cell suspension of the peripheral blood to be tested is detected, and the expression of the antibodies on CD45-SSC, CD36-CD64, CD14-CD64 and CD16-CD14 and the ratio of the three monocyte subtypes are analyzed in turn to obtain the antibody expression pattern of the peripheral blood to be tested; and then the antibody expression pattern is compared with that of a normal control population.
Citation Information
Patent Citations
Combined reagent for detecting acute myelocytic leukemia cells and system thereof
CN109655616A
Antibody composition for myeloid tumor immunotyping and application thereof
CN114213540A
Methods and Means for Monitoring Disruption of Tissue Homeostasis in the Total Body
US20140024019A1
